Annual Cash & Cash Equivalents
$220.50 K
-$1.65 M-88.24%
June 30, 2024
Summary
- As of February 7, 2025, RENB annual cash & cash equivalents is $220.50 thousand, with the most recent change of -$1.65 million (-88.24%) on June 30, 2024.
- During the last 3 years, RENB annual cash & cash equivalents has fallen by -$20.44 million (-98.93%).
- RENB annual cash & cash equivalents is now -98.93% below its all-time high of $20.66 million, reached on June 1, 2021.
Performance
RENB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$220.60 K
+$100.00+0.05%
September 30, 2024
Summary
- As of February 7, 2025, RENB quarterly cash and cash equivalents is $220.60 thousand, with the most recent change of +$100.00 (+0.05%) on September 30, 2024.
- Over the past year, RENB quarterly cash and cash equivalents has dropped by -$302.90 thousand (-57.86%).
- RENB quarterly cash and cash equivalents is now -98.93% below its all-time high of $20.66 million, reached on June 1, 2021.
Performance
RENB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RENB Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -88.2% | -57.9% |
| 3 y3 years | -98.9% | -57.9% |
| 5 y5 years | -98.2% | -57.9% |
RENB Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -98.9% | at low | -98.4% | +0.1% |
| 5 y | 5-year | -98.9% | at low | -98.9% | +0.1% |
| alltime | all time | -98.9% | -100.0% | -98.9% | -100.0% |
Renovaro Biosciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $220.60 K(+0.0%) |
| Jun 2024 | $220.50 K(-88.2%) | $220.50 K(-29.5%) |
| Mar 2024 | - | $312.70 K(+28.2%) |
| Dec 2023 | - | $244.00 K(-53.4%) |
| Sep 2023 | - | $523.50 K(-72.1%) |
| Jun 2023 | $1.87 M(-79.6%) | - |
| Jun 2023 | - | $1.87 M(-36.4%) |
| Mar 2023 | - | $2.95 M(-28.4%) |
| Dec 2022 | - | $4.12 M(-48.3%) |
| Sep 2022 | - | $7.97 M(-13.1%) |
| Jun 2022 | $9.17 M(-55.6%) | $9.17 M(-17.7%) |
| Mar 2022 | - | $11.15 M(-18.7%) |
| Dec 2021 | - | $13.71 M(-10.9%) |
| Sep 2021 | - | $15.38 M(-25.6%) |
| Jun 2021 | $20.66 M(+137.6%) | $20.66 M(+356.5%) |
| Mar 2021 | - | $4.53 M(+32.2%) |
| Dec 2020 | - | $3.43 M(-42.6%) |
| Sep 2020 | - | $5.97 M(-31.4%) |
| Jun 2020 | $8.70 M(-29.2%) | $8.70 M(-20.5%) |
| Mar 2020 | - | $10.94 M(+26.8%) |
| Dec 2019 | - | $8.63 M(-22.5%) |
| Sep 2019 | - | $11.14 M(-9.3%) |
| Jun 2019 | $12.28 M(-21.3%) | $12.28 M(+19.6%) |
| Mar 2019 | - | $10.27 M(-22.4%) |
| Dec 2018 | - | $13.24 M(-1.2%) |
| Sep 2018 | - | $13.41 M(-14.1%) |
| Jun 2018 | $15.60 M | $15.60 M(-8.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $17.02 M(+638.0%) |
| Dec 2017 | - | $2.31 M(-21.7%) |
| Sep 2017 | - | $2.94 M(-25.3%) |
| Jun 2017 | $3.94 M(>+9900.0%) | $3.94 M(>+9900.0%) |
| Mar 2017 | - | $33.70 K(-71.3%) |
| Dec 2016 | - | $117.60 K(+271.0%) |
| Sep 2016 | - | $31.70 K(+35.5%) |
| Jun 2016 | $23.40 K(-94.4%) | $23.40 K(-84.5%) |
| Mar 2016 | - | $151.20 K(-71.5%) |
| Dec 2015 | - | $531.30 K(-49.3%) |
| Sep 2015 | - | $1.05 M(-69.5%) |
| Jun 2015 | $421.10 K(-86.0%) | - |
| Mar 2015 | - | $3.43 M(+14.2%) |
| Dec 2014 | $3.01 M(>+9900.0%) | $3.01 M(+403.4%) |
| Sep 2014 | - | $597.70 K(+230.2%) |
| Jun 2014 | - | $181.00 K(+232.1%) |
| Mar 2014 | - | $54.50 K(>+9900.0%) |
| Dec 2013 | - | $0.00(0.0%) |
| Sep 2013 | - | $0.00(-100.0%) |
| Jun 2013 | - | $200.00(-97.0%) |
| Mar 2013 | $6700.00(+2133.3%) | $6700.00(+3250.0%) |
| Dec 2012 | - | $200.00(-91.3%) |
| Sep 2012 | - | $2300.00(+666.7%) |
| Jun 2012 | - | $300.00(0.0%) |
| Mar 2012 | $300.00(>+9900.0%) | $300.00(+200.0%) |
| Dec 2011 | - | $100.00 |
| Mar 2011 | $0.00 | - |
FAQ
- What is Renovaro Biosciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Renovaro Biosciences?
- What is Renovaro Biosciences annual cash & cash equivalents year-on-year change?
- What is Renovaro Biosciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Renovaro Biosciences?
- What is Renovaro Biosciences quarterly cash and cash equivalents year-on-year change?
What is Renovaro Biosciences annual cash & cash equivalents?
The current annual cash & cash equivalents of RENB is $220.50 K
What is the all time high annual cash & cash equivalents for Renovaro Biosciences?
Renovaro Biosciences all-time high annual cash & cash equivalents is $20.66 M
What is Renovaro Biosciences annual cash & cash equivalents year-on-year change?
Over the past year, RENB annual cash & cash equivalents has changed by -$1.65 M (-88.24%)
What is Renovaro Biosciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RENB is $220.60 K
What is the all time high quarterly cash and cash equivalents for Renovaro Biosciences?
Renovaro Biosciences all-time high quarterly cash and cash equivalents is $20.66 M
What is Renovaro Biosciences quarterly cash and cash equivalents year-on-year change?
Over the past year, RENB quarterly cash and cash equivalents has changed by -$302.90 K (-57.86%)